Medical Advocates
Dolutegravir/Abacavir/Lamivudine |
Last
Update:
March 30, 2018
 Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader |
March 2018
-
FULL-TEXT ARTICLE
A retrospective clinical audit of general practices in Australia to
determine the motivation for switch to
dolutegravir/abacavir/lamivudine and clinical outcomes.
Ferrer PE, Bloch M, Roth N, Finlayson R,
et al
Int J STD AIDS.
2018 Mar;29(3):300-305.
-
Intentional overdose of dolutegravir/abacavir/lamivudine (Triumeq) in a
26-year-old man.
van Dam PM, van Geffen MW, Havenith TR, Posthouwer D.
Antivir Ther.
2018 Mar 13.
-
Decreased absorption of dolutegravir and tenofovir disoproxil fumarate, but
not emtricitabine, in an HIV-infected patient following oral and
jejunostomy-tube administration.Brooks KM, Garrett KL, Kuriakose SS,
et al
Pharmacotherapy. 2017 May 27
-
Dolutegravir/abacavir/lamivudine
versus current ART in virally suppressed patients (STRIIVING): a
48-week, randomized, non-inferiority, open-label, Phase IIIb study.
Trottier B, Lake JE, Logue K, Brinson C,
et al
Antivir Ther.
2017;22(5):459-460
-
Cost-effectiveness of dolutegravir/abacavir/lamivudine
in HIV-1 treatment-Naive (TN) patients in France.
Pialoux G, Marcelin AG, Cawston H,
Expert Rev Pharmacoecon Outcomes Res.
2018 Feb;18(1):83-91
-
Dolutegravir/abacavir/lamivudine
versus current ART in virally suppressed patients (STRIIVING): a
48-week, randomized, non-inferiority, open-label, Phase IIIb study.
Trottier B, Lake JE, Logue K, Brinson C,
et al
Antivir Ther.
2017;22(4):295-305.
-
Cost-utility analysis of the fixed-dose combination of
dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients
in Spain.
Moreno Guillen S, Losa García JE, Berenguer Berenguer J, et al
Farm Hosp. 2017 Sep
1;41(5):601-610.
-
Bioequivalence of a dolutegravir, abacavir, and
lamivudine fixed-dose combination tablet and the effect of food.
Weller S, Chen S, Borland J, Savina P, Wynne B, Piscitelli SC.
J Acquir Immune Defic Syndr. 2014 Aug
1;66(4):393-8.
|
|
|
Dolutegravir/Abacavir/Lamivudine
|
|
New
and Noteworthy
ARV
Main Page